INM (InMed Pharmaceuticals) Ending Cash Position: $2.19 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INM InMed Pharmaceuticals Inc INM
28 GF Score
Price $1.30
! 2 Warning Signs
View Full Analysis

What is InMed Pharmaceuticals Ending Cash Position?

InMed Pharmaceuticals INM +0.78% 28 Ending Cash Position is $2.19 Mil as of Jun. 2026. GuruFocus rates INM with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

InMed Pharmaceuticals's Ending Cash Position for the quarter that ended in Jun. 2026 was $2.19 Mil.

InMed Pharmaceuticals's quarterly Ending Cash Position declined from Dec. 2025 ($6.96 Mil) to Mar. 2026 ($5.16 Mil) and declined from Mar. 2026 ($5.16 Mil) to Jun. 2026 ($2.19 Mil).

InMed Pharmaceuticals's annual Ending Cash Position increased from Jun. 2024 ($6.57 Mil) to Jun. 2025 ($10.74 Mil) but then declined from Jun. 2025 ($10.74 Mil) to Jun. 2026 ($2.19 Mil).

InMed Pharmaceuticals Ending Cash Position Related Terms

InMed Pharmaceuticals Ending Cash Position Historical Data

* Premium members only.

The historical data trend for InMed Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InMed Pharmaceuticals Ending Cash Position Chart

InMed Pharmaceuticals Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.18 8.91 6.57 10.74 2.19

InMed Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.74 9.33 6.96 5.16 2.19
INM
28GF Score
InMed Pharmaceuticals Inc INM
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InMed Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

InMed Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Jun. 2026 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=10.744+-8.55
=2.19

InMed Pharmaceuticals's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=5.159+-2.965
=2.19

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $2.19 Mil mean?
InMed Pharmaceuticals (INM) has a Ending Cash Position of $2.19 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on InMed Pharmaceuticals and its competitors.
Is InMed Pharmaceuticals' Ending Cash Position too high?
InMed Pharmaceuticals' current Ending Cash Position is $2.19 Mil. Overall, InMed Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does InMed Pharmaceuticals' Ending Cash Position compare to SNOA and GELS?
InMed Pharmaceuticals' Ending Cash Position of $2.19 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on InMed Pharmaceuticals and its competitors. InMed Pharmaceuticals's current Ending Cash Position is $2.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InMed Pharmaceuticals stock overvalued right now?
InMed Pharmaceuticals (INM) has a current Ending Cash Position of $2.19 Mil. The current Ending Cash Position is $2.19 Mil. InMed Pharmaceuticals' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For InMed Pharmaceuticals (INM), the current Ending Cash Position is $2.19 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

InMed Pharmaceuticals Business Description

Other Exchanges MWG:Germany
Address 885 West Georgia Street, Suite 1445, Vancouver, BC, CAN, V6C 3E8
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
28GF Score

Get the complete analysis for INM

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.30
Price